Consun Pharmaceutical Group (SEHK:1681) Lifts Earnings And Dividend On A Valuation That Still Looks Cheap

Consun Pharmaceutical Group (SEHK:1681) has drawn investor attention after reporting half year 2026 results along with an interim dividend announcement. The combination of earnings detail and cash distribution timing gives you fresh information to assess the stock.

Against this backdrop, Consun Pharmaceutical Group’s share price has softened, with a 7 day share price return of down 8.84% and a year to date share price return of down 12.48%. The 3 year total shareholder return of 231.95% points to strong longer term momentum that recent earnings and the higher interim dividend may now be testing in the market’s view of growth and risk.

Compare how Consun Pharmaceutical Group stacks up against other companies with strong financial profiles by scanning our hand picked list of solid balance sheet and fundamentals (438 results).

After that sharp pullback, even as Consun Pharmaceutical Group reports higher half year earnings and a larger interim dividend, the balance between downside risk and upside potential now comes down to what the current valuation actually implies.

Price-to-Earnings of 8.3x: Is it justified?

On the latest figures, Consun Pharmaceutical Group trades on a P/E of 8.3x, which screens as good value compared with both peers and the wider Hong Kong pharmaceuticals sector.

The P/E ratio compares the current HK$13.61 share price with the company’s earnings per share. For a profitable pharmaceutical group like Consun Pharmaceutical Group, this is a straightforward way for investors to see how much they are paying for each unit of current earnings.

According to Simply Wall St data, 1681 is described as trading at good value compared to peers and industry. Its P/E of 8.3x is below the Hong Kong Pharmaceuticals industry average of 14.3x and also below the estimated fair P/E of 15.3x. That gap signals that the market is pricing the stock at a discount to what the SWS fair ratio model suggests could be a more typical level if valuation moved closer to sector norms.

For investors who want to see how this fair ratio is calculated in more detail, it is worth reviewing the SWS model that underpins this comparison, including the inputs behind the 15.3x reference point and how it relates to earnings quality and growth.

Explore the SWS fair ratio for Consun Pharmaceutical Group

Result: Preferred multiple of Price-to-Earnings of 8.3x (UNDERVALUED)

However, Consun Pharmaceutical Group still faces risk if its earnings or revenue growth rates of 10.4% and 11.7% do not continue at similar levels.

Find out about the key risks to this Consun Pharmaceutical Group narrative.

Another view on Consun Pharmaceutical Group’s value

The SWS DCF model points to a very different picture for Consun Pharmaceutical Group. At a current share price of HK$13.61, Simply Wall St estimates a future cash flow value of HK$50.83, which frames the stock as undervalued on this method. How should an investor weigh such a wide gap?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Consun Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 258 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of optimism and concern around Consun Pharmaceutical Group, it makes sense to review the numbers and sentiment for yourself and move quickly. To see how the full picture of risks and rewards stacks up, take a closer look at the 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Consun Pharmaceutical Group?

If you stop with Consun Pharmaceutical Group, you risk missing other opportunities. Use the Simply Wall St screener to spot stocks that better match your goals.

• Target potential bargains by scanning 258 high quality undervalued stocks that combine solid fundamentals with prices that currently sit below their assessed worth.
• Build a sturdier portfolio by reviewing a 268 resilient stocks with low risk scores that focuses on companies with more resilient risk profiles.
• Get ahead of the crowd by checking a 614 high quality undiscovered gems that highlights quality businesses the broader market may be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com